Early Life
Mathias Boehringer is part of the Boehringer family, whose roots trace back to 1885 when Albert Boehringer founded Boehringer Ingelheim in Ingelheim am Rhein, Germany. The company started as a small tartaric acid factory and gradually evolved into a global pharmaceutical leader. The family has maintained a low public profile, prioritizing long-term business stability and scientific progress.
Rise to Success
Boehringer Ingelheim's success is built on its commitment to innovation and research. The company has developed into a global enterprise with three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company's revenue reached €25.6 billion in 2023, with a significant investment in R&D, approximately €6.2 billion. The family's strategy has been to maintain private ownership, avoiding the short-term pressures of public markets and enabling sustainable, long-term action.
Key Business Strategies
Boehringer Ingelheim focuses on innovation and partnerships with other pharmaceutical companies. The company has a strong presence in key markets, including North America, Europe, and Asia, with major production facilities in Ingelheim and Biberach, Germany, and the US headquarters in Ridgefield, Connecticut. The company emphasizes internal growth, sound financing, and focuses on providing quality medicines for human and animal health. The company is on track to launch up to 20 new treatments in Human Pharma by 2030, and 20 additional opportunities in Animal Health by 2026.
Philanthropy
While specific philanthropic initiatives of Mathias Boehringer are not widely publicized, the Boehringer Ingelheim group is committed to sustainable action and has established various initiatives. The company supports projects related to healthcare and animal well-being.